Xvivo Perfusion AB (publ)
XVIPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14,322 | $9,647 | $6,314 | $8,074 |
| - Cash | $416 | $546 | $247 | $399 |
| + Debt | $34 | $31 | $10 | $6 |
| Enterprise Value | $13,940 | $9,132 | $6,078 | $7,681 |
| Revenue | $822 | $598 | $415 | $258 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Gross Profit | $616 | $445 | $297 | $188 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| EBITDA | $289 | $81 | $39 | $39 |
| % Margin | 35.1% | 13.5% | 9.3% | 15.2% |
| Net Income | $172 | $92 | $18 | $8 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS Diluted | 5.44 | 3.07 | 0.62 | 0.28 |
| % Growth | 77.2% | 395.2% | 121.4% | – |
| Operating Cash Flow | $111 | $46 | $28 | -$12 |
| Capital Expenditures | -$71 | -$144 | -$131 | -$94 |
| Free Cash Flow | $41 | -$98 | -$103 | -$106 |